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In-transit metastasis (ITM) is a unique manifestation of intralymphatic tumor dissemination, characterized by
the presence of melanoma cells between the primary lesion and the draining regional lymph node basin that is
clinically associated with poor prognosis. In this study, we aimed to establish an experimental animal model of
melanoma ITM, as research progress in this field has been hampered by a lack of suitable experimental models.
We reproduced melanoma ITM in a mouse hind limb by transplanting melanoma cells into the footpad of a
mouse with lymphedema (LE). The tumor cells at the ITM site were highly proliferative, and mice with ITMs were
more likely than control mice to develop distant lymph node and lung metastases. Peritumoral lymphatic
vessels and tumor-associated blood vessels were increased in the primary tumor site of the LE mice. Our
established ITM melanoma mouse model enabled us to clarify the molecular determinants and pathophysiol-
ogy of ITM. This ITM model is also comparable to the unfavorable clinical behavior of melanoma ITM in humans
and, moreover, underlined the importance of lymphangiogenic factors in the tumor dissemination through the
lymphatic system.
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INTRODUCTION
Cutaneous melanoma is one of the most aggressive solid tumors,
and its incidence and mortality rates are increasing in most
countries (Marks, 2000). The aggressiveness of melanoma is
characterized by its high metastatic ability and resistance to
chemotherapy (Satyamoorthy and Herlyn, 2002; Soengas and
Lowe, 2003; Postovit et al., 2006; Gajewski, 2007). Cutaneous
melanoma metastasizes frequently via lymphatic systems, which
is one of the major prognostic factors for tumor recurrence and
survival (Balch et al., 2001). Once the melanoma has spread to
the lymphatic systems, only 40–50% of these patients survive for
5 years or more (Tsutsumida et al., 2005). In-transit metastasis
(ITM) is a unique pattern of intralymphatic metastasis and is
associated with poor prognosis (Pawlik et al., 2005a).
Traditionally, ITM has been regarded as a recurrent loco-
regional disease found in the dermis or subcutaneous tissue
between the primary melanoma and the regional lymph node
basin. This pattern of metastasis has a reported incidence of
5–10%, but is associated with significant morbidity, and may be
a source of eventual distant metastasis (Gershenwald and Fidler,
2002; Pawlik et al., 2005a, b). Eighty-six percent of patients
have been found to progress to systemic disease ranging from 2
to 244 months (median 16 months) following the development
of ITM. The overall 5-year survival and the median survival,
from the time of ITM diagnosis, have been reported as 12% and
19 months, respectively (Wong et al., 1990).
The molecular determinants and pathophysiology of ITM
are still poorly understood; one of the reasons seems to be a
lack of suitable experimental animal models. In this study, we
aimed to reproduce ITM of melanoma to clarify the
pathophysiology of ITM using mice models. ITM is known
to be promoted by disrupted lymph flow resulting from
regional lymph node basin intervention (Cascinelli et al.,
1986; Calabro et al., 1989; Wong et al., 1990; Zogakis et al.,
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2001; Pawlik et al., 2005b); hence, we hypothesized that ITM
could be reproduced when melanoma was transplanted to
the hind limb of a mouse with lymphedema (LE; Oashi et al.,
2011).
RESULTS
LE mice developed ITM of melanoma
To create ITM of melanoma, we developed a new experi-
mental animal model of acquired LE in the mouse hind limb
in animals with LE (see Figure 1; Oashi et al., 2011). Firefly
luciferase (luc)–expressing melanoma cells (B16-F10-luc2;
see Figure 2a) were transplanted to the LE hind limbs of mice
with LE.
At 24 days after tumor transplantation, two out of five LE
mice developed ITM in their LE hind limbs (see Figure 2b
and c), whereas non-LE mice developed no ITM. So far, we
have performed the same procedure in an additional eight
LE mice, and all of these mice successfully developed ITM
(data not shown).
High expression of the proliferation marker Ki-67 in ITM
A schematic representation of the experimental groups is
shown in Figure 3a. The percentage of Ki-67-positive tumor
cells was significantly higher in the ITM of LE mice (LE-ITM)
compared with either the tumor in the footpad (FP) of non-LE
mice (non-LE-FP) or LE mice (LE-FP; Po0.05), which
indicates the high proliferative activity of LE-ITM (see Figure
3b). There was no significant difference in the expression
level of Ki-67 between LE-FP and non-LE-FP.
Quantification of vessel area in tumor sections
The tumors were harvested and immunostained using anti-
CD31 antibody and anti-lymphatic vessel endothelial hyalur-
onan receptor (LYVE)-1 antibody for the histopathological
examinations (see Supplementary Materials online). The
quantitative results of tumor-associated blood vessel area
(BVA) are shown in Figure 3c. Tumor-associated blood
vessels were defined as CD31-positive/LYVE-1-negative
vessels located within the tumor mass and within an area of
100mm from the tumor border. Tumor-associated blood
vessels were homogeneously distributed throughout the
Figure 1. The lymphedema (LE) mouse. (a) After injecting patent blue dye into
the left paw, the left side inguinal skin was circumferentially incised. The
stained lymphatic vessels were carefully tied at three points with a 10–0 nylon
suture, and the subiliac and popliteal lymph nodes were resected. The skin
edges were sutured to underlying muscle, leaving a gap of 1–2mm between
the skin edges. Black arrow, popliteal lymph node; black arrowheads, ligations
of lymphatic vessels. Bar¼ 1mm. (b) Fluorescent lymphangiography of LE
mouse 8 weeks after the lymph node resection demonstrates disappearance of
major lymphatic trunks on the treated side. Normal, distinct vessel structure
was replaced by a bright, punctuate fluorescence pattern over a foggy
background. The bottom row represents the visual image. White arrow, treated
limb; white arrowhead, popliteal lymph node of the untreated limb.
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Figure 2. Luciferase (luc)-expressing B16-F10-luc2 cells cause in-transit
metastasis (ITM) in the lymphedema (LE) hind limb of a mouse. (a) Cultured
B16-F10-luc2 melanoma cells and B16-F10 parental melanoma cells were
immunostained with antibodies against luc (green). Nuclear DNA was labeled
with 4,6-diamidino-2-phenylindole (DAPI; blue). Bar¼ 100mm. (b) Forty-two
days after tumor transplantation into the LE hind limb of a mouse, ITMs were
seen. Bar¼ 1mm. (c) Histology of melanoma at the site of transplantation (top
row) and ITM (bottom row), both of which express luc. HE, hematoxylin and
eosin stains; LE-FP, LE-footpad; bar¼100 mm.
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tumors. This finding is similar to clinical cases (Giorgadze
et al., 2004). BVA was larger in LE-FP compared with either
non-LE-FP or LE-ITM (Po0.05). There was no statistically
significant difference between LE-ITM and non-LE-FP.
The quantitative results of peritumoral lymphatic vessel
area (LVA) are shown in Figure 3d. Peritumoral lymphatic
vessels were defined as LYVE-1-positive vessels within an
area of 200 mm from the tumor border. Peritumoral lymphatic
vessels were chosen for the evaluation of LVA, because
intratumoral lymphatic vessels are reported to be poorly
functional because of high intratumoral pressure and not
required for lymphatic metastasis (Padera et al., 2002; Wong
et al., 2005). Conversely, lymphatic vessels in the tumor
periphery are functional and can drain colloids from the
tumor.
In all experimental groups, peritumoral lymphatic vessels
frequently had open lumina, although intratumoral lymphatic
vessels frequently exhibited a thin-walled, collapsed mor-
phology. The LVA was larger in LE-FP compared with non-LE-
FP (Po0.05). Although LVA in LE-FP was larger compared
with LE-ITM, the difference did not reach statistical sig-
nificance (P¼0.12). There was no statistically significant
difference between LVA of LE-ITM and non-LE-FP.
In vivo bioluminescence imaging
Luc-expressing B16-F10-luc2 melanoma cells were
transplanted into the left FP of both non-LE and LE mice,
and serially imaged using bioluminescence imaging. To
ascertain the contribution of irradiation to the metastatic
pattern, the mice that underwent surgery without preopera-
tive irradiation (IR () mice) were prepared. The melanoma
cells were also transplanted to the left FP of IR ()
mice. Three representative mice are shown for each subline
(see Figure 4a).
Seven days after tumor transplantation, signals from
melanoma cells could be seen not only at the left FP but
also within the left hind limb of the LE mouse, which
represents pocket of ITM of melanoma. On day 14, a signal
from the tumor in the left axillary lymph node could be
clearly identified in the LE mouse (which was visually
confirmed at necropsy). Fluorescence lymphangiography of
tumors transplanted into LE mice revealed the new lymphatic
flow from the left hind limb to the left axillary lymph node,
which was not observed in non-LE mice (see Figure 4b). By
day 20, signals from the ITM within the left hind limb of the
LE mouse became remarkably enlarged. The LE mouse died
because of tumor progression at around day 27.
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Figure 3. Characterization of in-transit melanoma. The tumors were harvested from five lymphedema (LE) mice and six non-LE mice at 24 days after
transplantation for the histopathological evaluation. Three LE mice developed in-transit metastasis (ITM), which is the number of the ITM specimen.
(a) Schematic representation of experimental groups. (b) The ratio of Ki-67-positive cells over the total number of tumor cells. Representative microscopic
views are shown in the bottom row. Bar¼ 20mm. (c) The area of tumor-associated CD31-positive/lymphatic vessel endothelial hyaluronan receptor
(LYVE)-1-negative blood vessels. Representative microscopic views are shown in the bottom row. Bar¼ 50 mm. (d) The area of peritumoral LYVE-1-positive
lymphatic vessels. Representative microscopic views are shown in the bottom row. Bar¼ 50mm. HPF, high-power field; LE-FP, LE-footpad. N¼3–6,
meanþ SD, *Po0.05 after Student’s t-test.
www.jidonline.org 539
K Oashi et al.
Animal Model of Melanoma In-Transit Metastasis
Day 7
1.2
1.5
1.0
0.5
1.0
x10 6
0.8
x10
7
x10
7
x10 8
x10 6
0.6
0.4
4.8 7.0
6.0
1.2
1.2
6.0
4.0
2.0
1.0
0.8
0.6
0.4
0.2
1.0
0.2
0.6
0.4
0.2
5.0
4.0
3.0
2.0
1.0
6.0
5.0
4.0
4.6
4.4
4.2
x10 5
x10 6
x10 6
x10 6
x10 6
x10
7
x10 8
x10
7
x10 8
x10 6 x10
7
x10
7
x10 8
x10 8
x10
7
x10
7
x10
7
x10 8 x10 8
x10 6
x10
7
x10 8
x10 6
x10 5
4.0
3.8
3.6
6.0
1.4 3.0
4.0 2.0
1.5
1.0
0.5
1.5
1.0
0.5
3.0
2.0
1.0
2.5
2.0
1.5
1.0
0.5
1.2
1.0
0.1
0.6
0.4
0.2
4.0
2.0
1.4
4.0
5.0
4.0
3.0
2.0
1.0
4.0
3.0
2.0
1.0
3.0
2.0
1.0
2.0 4.0
3.0
2.0
1.0
1.5
1.0
0.5
1.2
1.0
0.1
0.6
0.4
4.0 1.5
3.0
0.8
1.5
1.0
0.5
0.6
0.4
0.2
2.5
2.0
1.5
1.0
0.5
1.0
0.5
3.0
2.0
1.0
1.2
1.0
0.2
0.6
0.4
1.0
1.0
2.5
2.0
1.5
1.0
0.5
0.1
0.1
0.6
0.6
0.4 0.4
0.2 0.2
N
on
-L
E 
m
ou
se
IR
 (–
) m
ou
se
LE
 m
ou
se
Day 14 Day 20 Day 28 Day 35 Day 42
Figure 4. Bioluminescent imaging of a lymphedema (LE) and a non-LE mouse. Three mice in each group were used for the in vivo bioluminescence imaging,
and representative images of each group are presented. (a) Note signal scale differences between panels. The LE mouse was dead before day 28. Top
rows of the each mouse represent prone position, and bottom rows of the each mouse represent supine position. (b) Fluorescence lymphangiography of a
tumor-transplanted LE mouse (35 days after transplantation). Dotted line represents the outline of the mouse. IR () mouse, mouse that underwent surgery
without preoperative irradiation.
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Conversely, a signal from melanoma cells was identified
within the left FP of the non-LE mouse. By day 42, this signal
in the left FP of the non-LE mouse had gradually enlarged. On
day 42, a detectable tumor signal arose from the left popliteal
lymph node in the non-LE mouse (and this was visually
confirmed at necropsy). In the case of IR () mouse, the signal
in the left FP showed similar growth pattern to the non-LE
mouse, and a small signal from the ITM could be detected
within the left hind limb on day 42.
LE mice developed more lung metastases
The tumor volume at the primary transplanted site 24 days
after transplantation failed to show any difference between
the non-LE and the LE mice (see Figure 5a).
To determine the total burden of tumor metastasized to the
lung, the lungs were homogenized and total luc activity of the
lung extract was examined with luminometry (see Figure 5b).
The relative light units of lung extract were significantly
higher in the LE mice (Po0.05), indicating that the LE mice
had a greater burden of lung metastases. There was a robust
relationship between cell number and relative light units
(r2¼ 0.98; see Supplementary Figure S1a online), as well as
relative light units and luc concentration (r2¼0.99; see
Supplementary Figure S1b online).
DISCUSSION
ITM is a unique manifestation of intralymphatic tumor
dissemination, characterized by the presence of melanoma
in either cutaneous or subcutaneous tissue situated between
the primary tumor and the draining regional lymph node
basin.
In this study, we have succeeded in reproducing ITM of
melanoma in the mouse hind limb using LE experimental
model mice (Oashi et al., 2011). To our knowledge, an
experimental animal model for ITM is previously unreported.
This ITM animal model enabled us to directly compare the
nature of ITM with primary melanoma, using a genetically
similar inbred mouse strain and melanoma cell line. To
further represent clinical cases, we did not use an immuno-
compromised mouse metastasis model but used a syngenic
mouse metastasis model, because immune responses are
closely associated with the progression of melanoma
(Parmiani et al., 2007; Hodi et al., 2010). The mice that
underwent surgery without preoperative irradiation (IR ()
mice) showed mild LE and early lymphatic regeneration (data
not shown). Given that it took longer time to induce ITM in IR
() mice, the severity of lymphostasis is associated with the
occurrence of ITM.
The primary tumor in the LE mice (LE-FP) had a larger area
of peritumoral lymphatic vessels (see Figure 3d). Quantitative
reverse-transcription PCR was performed to quantify the
expression of Vegf-C in the tumor tissues. The expression of
Vegf-C in the tumor tissues showed no difference between
groups (data not shown). Given that the expression levels of
Vegf-C were similar between groups, one possible reason for
the enlargement of LVA in the LE-FP is the result of the
morphological change in lymphatic vessels, such as abnor-
mal dilation and curvature caused by lymphostasis (Kinmonth
and Taylor, 1954; Tabibiazar et al., 2006; Ogata et al., 2007;
Ikomi et al., 2008; Stanton et al., 2009). Another reason for
the large LVA is that, in the LE mice, disturbed flow of
interstitial fluid around the tumor resulted in the local
accumulation of vascular endothelial growth factor C
(VEGF-C) produced by the tumor cells, stromal cells, and
lymphatic endothelial cells around the tumor in spite of the
uniform level of Vegf-C expression. Such a local accumula-
tion of VEGF-C around the tumor might promote lymphan-
giogenesis at the primary tumor site.
VEGF-C has been reported not only to promote primary
tumor lymphangiogenesis but also to induce lymph node
lymphangiogenesis, which might facilitate further metastatic
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Figure 5. Tumor size and lung metastasis. The tumor volume at the primary
transplanted site and the luciferase activity of the lung extract of five
lymphedema (LE) mice and six non-LE mice were determined 24 days after
transplantation. (a) The volume of the tumor was calculated with the following
formula: lengthwidth depth/2. Representative macroscopic views are shown
in the bottom row. (b) Lungs were excised and homogenized and total luciferase
activity was determined with a standard ex vivo luciferase assay. Representative
macroscopic views are shown in the bottom row. No black nodule (lung
metastasis of melanoma cells) was observed visually. RLUs, relative light units.
N¼ 5–6, meanþ SD, *Po0.05 after Student’s t-test.
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tumor spread throughout the lymphatic system and to
distant organs (Mandriota et al., 2001; Skobe et al., 2001;
Padera et al., 2002; Krishnan et al., 2003; Hirakawa
et al., 2007; Sleeman and Thiele, 2009; Christiansen and
Detmar, 2011). It is suspected that the ability of VEGF-C to
induce lymph node lymphangiogenesis promotes metastasis
via distal lymph nodes, the thoracic duct, and the
blood vascular system to distant organs (Hirakawa et al.,
2007). This model is supported by the observation in the
present study that LE mice were more likely than control mice
to develop distant lymph node and lung metastases.
There are three other possible reasons why LE mice
had a larger burden of lung metastases, except for the
lymphangiogenic factor–mediated pathway. First, signifi-
cantly increased Ki-67 expression was seen in the LE-ITM
(see Figure 3b). ITM has a high proliferative activity,
which means that it has an aggressive biological behavior
and hence a greater potential to form distant metastasis. The
importance of examining tumor proliferation has been
underscored by the addition of mitotic rate to the 7th
edition of the American Joint Committee on Cancer
melanoma-staging system (Balch et al., 2009). Compared
with mitotic rate, the expression level of nuclear antigen
Ki-67 may be a better assessment of proliferation, as
Ki-67 is expressed in mitosis as well as during the G1, S,
and G2 phases of the cell cycle in proliferating cells
(Gerdes et al., 1983). Ki-67 expression has also been shown
to have prognostic value in melanoma (Tu et al., 2011) and
other cancers (most notably in breast cancer; Gerdes et al.,
1983; Railo et al., 1993; Keshgegian and Cnaan, 1995;
Bettencourt et al., 1996; Fitzgibbons et al., 2000; Mucci
et al., 2000). Given that the tumor cells and the animals used
in this study were genetically identical, high expression of
Ki-67 in ITM may have been caused by the environment
surrounding the tumor or the selection of a highly prolif-
erative tumor variant.
Second, large tumor-associated BVA (see Figure 3c) might
increase the chance that invasive tumor cells enter the blood
vascular system, which resulted in the formation of distant
metastasis, with an increased numbers of disseminating
tumor cells transplanted to distant organs.
The third possible reason is that tumor immunity was
disturbed by removing the regional lymph node basin
and following lymphostasis, which facilitated the tumor
dissemination. Lymphatics are an important pathway for
immune cell trafficking (e.g., lymphocytes, Langerhans
cells, and macrophages), antigen delivery to the lymph node,
and clearance of foreign antigens (Olszewski et al., 1990).
The occurrence of malignancy in the setting of LE is
the suspected consequence of impaired local immune
surveillance due to the disruption of trafficking of immuno-
competent cells in the lymphedematous region (Ruocco
et al., 2002, 2007).
The LVA in LE-ITM was not as large as LE-FP. This
discrepancy may be explained by the highly proliferative
nature of ITM. Straume et al. (2003) found that decreased
lymphatic vessel density was present in thicker and more
proliferative tumors. The authors suggested that large and
aggressive melanomas might destroy the lymphatics and thus
made them less detectable by immunohistochemistry
(Straume et al., 2003).
In this study, we have succeeded in creating an experi-
mental animal model of melanoma ITM. Our established ITM
melanoma mouse model enabled us to clarify the molecular
determinants and pathophysiology of ITM. This ITM model is
also comparable to the unfavorable clinical behavior of
melanoma ITM in humans and, moreover, underlined the
importance of lymphangiogenic factors in the tumor dis-
semination through the lymphatic system.
MATERIALS AND METHODS
Animals
Male C57BL/6N mice weighing between 18 and 20 g were
purchased from Sankyo Labo Service (Tokyo, Japan). All experiments
were performed under general anesthesia. Anesthesia was
induced and maintained by an intraperitoneal injection of pento-
barbital (30mg kg1 body weight) or 2–3% (flow rate) isoflurane
inhalation. Chronic LE in the hind limb of a mouse was created by
radiation treatment and one operation—surgical division of the
superficial and deep lymphatics as previously described (see
Figure 1; Oashi et al., 2011).
Four weeks after the surgery, the B16-F10-luc2 melanoma cells
were transplanted to the hind limb as described in the next
paragraph. All animal studies were conducted in accordance with
Guidelines for the Care and Use of Laboratory Animals at the
Hokkaido University. All procedures used in this study were
approved by the local committee (Animal Care and Use Committee,
Hokkaido University).
Cell lines
The B16-F10-luc2 cell line was purchased from Caliper Lifesciences
(Hopkinton, MA). This luc-expressing cell line was stably transfected
with firefly luc gene (luc2). The parental line B16-F10 was obtained
from the ATCC (Rockville, MD), and B16-F10-luc2 was established
by transducing a lentivirus containing the luc2 gene under the
control of human ubiquitin C promoter. This cell line was
maintained in RPMI 1640 medium (ATCC catalog no. 30-2001)
with 10% fetal bovine serum. Before tumor challenge, B16-F10-luc2
cells were grown in supplemented RPMI 1640, harvested, washed
twice, and resuspended in Hanks’ balanced salt solutions. Further,
the cell suspension was injected into the FP at a dose of 4 105 in
0.05ml of Hanks’ balanced salt solution (Giavazzi and Garofalo,
2001). The tumors and the lungs were harvested at 24 days after
tumor induction for the histopathological examinations and ex vivo
luc assay.
Assessment of Ki-67 expression
The tumors were harvested from five LE mice and six non-LE mice at
24 days after transplantation for the evaluation of Ki-67 expression.
Three LE mice developed ITM, which is the number of the ITM
specimen. Five high-power fields ( 400) of tumor areas with the
highest density of positive nuclear staining were chosen from each
slide. The percentage of Ki-67-positive tumor cells was then
determined by relating the total number of positively stained tumor
cells to the total number of tumor cells in all five fields. The mean
value was calculated for each section.
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Tumor blood vessel and lymphatic vessel area
The tumors were harvested from five LE mice and six non-LE mice at
24 days after transplantation for the evaluation of vessel area. Three
LE mice developed ITM, which is the number of the ITM specimen.
Sections were examined using an Olympus IX-61 microscope. Digital
images were captured with an Olympus DP 70 digital camera and
were processed with an Olympus DP Controller (all from Olympus
Optical, Tokyo, Japan). The quantification of the vascular area was
performed using the Image J software (NIH, Baltimore, MD). To
analyze the LVA and BVA, the immunostained sections were first
scanned at  100 magnifications, and the spot with the greatest
vascularity within and around the tumor (hot spots) was selected for
further evaluation. Tumor borders were determined on serial sections
using hematoxylin and eosin stains or luc immunostaining.
The peritumoral LVAs were determined in four high-power fields
( 400), and the mean area was calculated for each section. Single
LYVE1-positive cells were considered to be macrophages and
excluded from the analysis. The tumor-associated BVA was
determined in eight high-power fields ( 400) and the mean area
was calculated for each section.
In vivo optical imaging
Three mice in each group were used for the in vivo bioluminescence
imaging, and representative images of each group were presented in
Figure 4. Before imaging, mice were anesthetized with 2%
isoflurane, and 150mgml1 of D-luciferin (VivoGlo Luciferin,
In Vivo Grade, Promega, Madison, WI) in normal saline was
intraperitoneally injected at a dose of 150mg kg1 body weight. The
tumor site was shaved to minimize the amount of light absorbed by
black fur, and imaged after 10–20minutes. A cryogenically cooled
IVIS system (Xenogen, Alameda, CA) coupled with a data acquisition
PC running the LivingImage software (Xenogen) was used to detect
photon emission from tumor-bearing mice (Contag et al., 1997;
Rehemtulla et al., 2000; Craft et al., 2005; Xing et al., 2008).
Fluorescent lymphangiography was performed 15minutes after
injecting 2ml of a 2-mgml1 solution of indocyanine green
subcutaneously into the paws or just proximal to the tumor. The
mice were then observed using the Near-infrared fluorescence
camera system (Photodynamic Eye; Hamamatsu Photonics, Hama-
matsu, Japan).
Quantification of lung metastasis
Twenty-four days after tumor transplantation, five LE mice and six
non-LE mice were killed by overdose of diethyl ether. The entire lung
was collected from each mouse, washed with phosphate-buffered
saline, and frozen on dry ice in a 2-ml microtube immediately after
collection and stored at 80 1C. Lung tissues were soaked in 800ml
of Luciferase Cell Culture Lysis Reagent in Luciferase Assay System
(E1500, Promega) and crushed twice each at 4,000 r.p.m. for
30 seconds with a 5.5-mm-diameter stainless bead using a Micro
Smash MS-100 (TOMY, Tokyo, Japan). The samples were frozen and
thawed three times using alternating liquid nitrogen and a 37 1C heat
block, vortexed for 15minutes, and centrifuged for 3minutes at
10,000g. The supernatant was transferred to 1.5-ml tubes. After adding
another 200ml of Luciferase Cell Culture Lysis Reagent to the pellet,
vortex and centrifuge processes were repeated. The second super-
natant was added to the first one, and then nearly 1ml of total lung
extract was stored at 80 1C until assayed (Manthorpe et al., 1993).
Luc activity was assayed using a GloMax 20/20n Luminometer
(Promega). Twenty microliters of lung extract was added to 100ml of
Luciferase Assay Reagent in Luciferase Assay System (E1500,
Promega) in a luminometer tube, and sample light units were
recorded by performing a 2-second measurement delay followed by
a 10-second measurement read for luc activity.
The in vitro luc assay revealed a high correlation between the
number of B16-F10-luc2 melanoma cells and the bioluminescent
activity (see Supplementary Figure S1a online). The bioluminescent
activity was not disturbed under existence of lung extract (see
Supplementary Figure S1b online). Hence, the result of ex vivo luc
assay was considered to represent the tumor burden of lung
metastasis.
Statistical analysis
All error bars represent SD of the mean unless otherwise designated.
The difference between groups was considered statistically signifi-
cant when the P-value was lower than 0.05 after Student’s t-test.
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